- Home
- GLMD vs ENVB Comparison
GLMD vs ENVB Comparison
Compare GLMD & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- ENVB
- Stock Information
- Founded
- GLMD 2000
- ENVB 1994
- Country
- GLMD Israel
- ENVB United States
- Employees
- GLMD N/A
- ENVB N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- GLMD Health Care
- ENVB Health Care
- Exchange
- GLMD Nasdaq
- ENVB Nasdaq
- Market Cap
- GLMD 4.6M
- ENVB 4.2M
- IPO Year
- GLMD 2014
- ENVB N/A
- Fundamental
- Price
- GLMD $3.03
- ENVB $0.31
- Analyst Decision
- GLMD
- ENVB Strong Buy
- Analyst Count
- GLMD 0
- ENVB 1
- Target Price
- GLMD N/A
- ENVB $10.00
- AVG Volume (30 Days)
- GLMD 47.4K
- ENVB 160.9K
- Earning Date
- GLMD 01-03-2025
- ENVB 11-14-2024
- Dividend Yield
- GLMD N/A
- ENVB N/A
- EPS Growth
- GLMD N/A
- ENVB N/A
- EPS
- GLMD N/A
- ENVB N/A
- Revenue
- GLMD N/A
- ENVB N/A
- Revenue This Year
- GLMD N/A
- ENVB N/A
- Revenue Next Year
- GLMD N/A
- ENVB N/A
- P/E Ratio
- GLMD N/A
- ENVB N/A
- Revenue Growth
- GLMD N/A
- ENVB N/A
- 52 Week Low
- GLMD $2.56
- ENVB $0.30
- 52 Week High
- GLMD $23.80
- ENVB $2.92
- Technical
- Relative Strength Index (RSI)
- GLMD 49.41
- ENVB 32.63
- Support Level
- GLMD $2.81
- ENVB $0.34
- Resistance Level
- GLMD $3.35
- ENVB $0.37
- Average True Range (ATR)
- GLMD 0.27
- ENVB 0.03
- MACD
- GLMD 0.06
- ENVB 0.00
- Stochastic Oscillator
- GLMD 56.63
- ENVB 1.22
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.